Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert McEwen

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Oncotarget|March 19, 2016
Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screenJames T Lynch, Robert McEwen, Claire Crafter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2026
Post-Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid TumorsVicky Makker, Jung-Yun Lee, Do-Youn Oh, et al.
Nucleic Acids Research|April 10, 2016
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer researchZhongwu Lai, Aleksandra Markovets, Miika Ahdesmaki, et al.
Oncotarget|May 17, 2018
Functional significance of co-occurring mutations in <i>PIK3CA</i> and <i>MAP3K1</i> in breast cancerAlvaro Avivar-Valderas, Robert McEwen, Amir Taheri-Ghahfarokhi, et al.
Plos One|September 4, 2020
STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real worldNorah J Shire, Alyssa B Klein, Asieh Golozar, et al.
Oncotarget|March 17, 2016
Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkersJames R Bradford, Mark Wappett, Garry Beran, et al.
Nature Reviews. Cancer|April 27, 2016
Defining actionable mutations for oncology therapeutic developmentT Hedley Carr, Robert McEwen, Brian Dougherty, et al.
Cancer Research|April 19, 2017
SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung CancerEiki Ichihara, David Westover, Catherine B Meador, et al.
Molecular Cancer Therapeutics|February 28, 2018
Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast CancerChrysiis Michaloglou, Claire Crafter, Rasmus Siersbaek, et al.
Oncotarget|May 14, 2019
Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in <i>Brca2</i>-mutant mammary tumoursLiliana D Ordonez, Trevor Hay, Robert McEwen, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Oncotarget|March 19, 2016
Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screenJames T Lynch, Robert McEwen, Claire Crafter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2026
Post-Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid TumorsVicky Makker, Jung-Yun Lee, Do-Youn Oh, et al.
Nucleic Acids Research|April 10, 2016
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer researchZhongwu Lai, Aleksandra Markovets, Miika Ahdesmaki, et al.
Oncotarget|May 17, 2018
Functional significance of co-occurring mutations in <i>PIK3CA</i> and <i>MAP3K1</i> in breast cancerAlvaro Avivar-Valderas, Robert McEwen, Amir Taheri-Ghahfarokhi, et al.
Plos One|September 4, 2020
STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real worldNorah J Shire, Alyssa B Klein, Asieh Golozar, et al.
Oncotarget|March 17, 2016
Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkersJames R Bradford, Mark Wappett, Garry Beran, et al.
Nature Reviews. Cancer|April 27, 2016
Defining actionable mutations for oncology therapeutic developmentT Hedley Carr, Robert McEwen, Brian Dougherty, et al.
Cancer Research|April 19, 2017
SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung CancerEiki Ichihara, David Westover, Catherine B Meador, et al.
Molecular Cancer Therapeutics|February 28, 2018
Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast CancerChrysiis Michaloglou, Claire Crafter, Rasmus Siersbaek, et al.
Oncotarget|May 14, 2019
Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in <i>Brca2</i>-mutant mammary tumoursLiliana D Ordonez, Trevor Hay, Robert McEwen, et al.
Pageof 3